Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

 

Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market
Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market

Community-acquired bacterial pneumonia (CABP) is a type of pneumonia that is contracted outside of a hospital or healthcare setting. The treatment for CABP involves antibiotics, which are medications that kill the bacteria causing the infection. The global market for drugs used to treat CABP is expected to grow in the coming years due to the increasing prevalence of pneumonia and the development of new antibiotics.

The Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market is highly competitive, with several pharmaceutical companies vying for a share of the market. Some of the key players in this market include Pfizer Inc., Merck & Co. Inc., Roche Holdings AG, GlaxoSmithKline Plc, and AstraZeneca Plc.

Factors such as increasing awareness about pneumonia, the rising geriatric population, and the development of new antibiotics are expected to drive the growth of the Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market in the coming years. However, the emergence of antibiotic-resistant strains of bacteria and the high cost of new antibiotics may pose a challenge to the growth of this market.

The high incidence of community-acquired pneumonia is anticipated to increase demand for medications that treat CABP, which will fuel market expansion throughout the forecast period. For instance, an article from the Asian Pacific Association of Respirology from 2017 states that in Central Vietnam, the incidence of all-cause CAP was predicted to be 0.81 per 1,000 people each year, increasing to 6.95 per 1,000 people each year among those who were 75 or older.

Moreover, the impact of HIV was a major factor in the rising prevalence of CAP. For instance, according to the Asian Pacific Association of Respirology, a 2017 paper claims that in 2017, HIV was the primary cause of CAP if untreated, which was linked to a 17- to 35-fold rise in pneumococcal pneumonia in the Sub-Saharan Africa area.

Comments

Popular posts from this blog

The Role of the Foodservice Industry in Driving the French Fries Market

Market Share and Revenue Analysis of the Microdermabrasion Devices Market

The Growing Demand for Healthcare Staffing Market: Trends and Opportunities